↓ Skip to main content

Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS…

Overview of attention for article published in Calcified Tissue International, June 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
71 Mendeley
Title
Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)
Published in
Calcified Tissue International, June 2018
DOI 10.1007/s00223-018-0437-x
Pubmed ID
Authors

Nicola Napoli, Bente. L. Langdahl, Östen Ljunggren, Eric Lespessailles, George Kapetanos, Tomaz Kocjan, Tatjana Nikolic, Pia Eiken, Helmut Petto, Thomas Moll, Erik Lindh, Fernando Marin

Abstract

This study aimed to describe clinical outcomes in patients prescribed teriparatide and followed up for 18 months after stopping the drug in real-life conditions. The Extended Forsteo® Observational Study analysed incident clinical fractures in 6-month intervals using logistic regression with repeated measures. Changes in back pain (visual analogue scale) and health-related quality of life (HRQoL; EQ-5D questionnaire) were analysed using mixed models for repeated measures. Patients were analysed if they had a post-baseline visit, regardless of whether and for how long they took teriparatide. Of 1531 patients analysed (90.7% female, mean age: 70.3 years), 76 (5.0%) never took teriparatide. Median treatment duration was 23.6 months. The adjusted odds of clinical fracture decreased by 47% in the > 12- to 18-month treatment period (p = 0.013) compared with the first 6-month period, with no statistically significant reduction in the > 18- to 24-month interval. The clinical fracture rate remained stable during the 18 months' post-teriparatide, when approximately 98% of patients took osteoporosis medication (51% bisphosphonates). Clinical vertebral fractures were reduced at every time period compared with the first 6 months. Adjusted mean back pain scores decreased and EQ-5D scores increased significantly at each post-baseline observation. In a real-life clinical setting, the risk of clinical fractures declined during 24 months of teriparatide treatment. This reduction was maintained 18 months after stopping teriparatide. In parallel, patients reported significant improvements in back pain and HRQoL. The results should be interpreted in the context of the non-controlled design of this observational study.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 71 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 22 31%
Student > Ph. D. Student 9 13%
Student > Bachelor 6 8%
Other 4 6%
Student > Doctoral Student 3 4%
Other 10 14%
Unknown 17 24%
Readers by discipline Count As %
Unspecified 22 31%
Medicine and Dentistry 17 24%
Nursing and Health Professions 6 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 1%
Biochemistry, Genetics and Molecular Biology 1 1%
Other 4 6%
Unknown 20 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2018.
All research outputs
#18,345,259
of 23,577,654 outputs
Outputs from Calcified Tissue International
#1,467
of 1,803 outputs
Outputs of similar age
#220,007
of 302,830 outputs
Outputs of similar age from Calcified Tissue International
#17
of 26 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,803 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 302,830 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.